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This article presents the results of a controlled clinical study of 3 shortcourse regimens conducted
at the Tuberculosis Research Centre, Madras, in collaboration with the British Medical Research
Council and the World Health Organization.
The patients came from the poorest sections of the population of Madras City. They were all aged
12 years or more, and had newly diagnosed previously untreated pulmonary tuberculosis with sputum
cultures positive for M. tuberculosis. All the patients were treated on an ambulatory basis and re-
ceived every dose under full supervision in the clinic.
Patients were randomly allocated to three regimens. In all there was an initial intensive daily phase
of 2 months, and this was followed by a twice-weekly intermittent phase of 3 or 5 months.
In the first regimen (regimen RSHZ/S2H2Z2 - 5), the patients were treated with 4 drugs: rifam-
picine, streptomycin, isoniazid and pyrazinamide, daily for 2 months. Rifampicin was discontinued
thereafter, and the treatment was continued with the remaining 3 drugs given twice-weekly for
3 months, ie. a total of 5 months.
The second regimen (regimen RSHZ/S2H2Z2 - 7) was similar to the first regimen in the daily
phase, but the twice-weekly phase was longer by 2 months so that the total duration was 7 months
Rifampicin was excluded from the third regimen, regimen SHZ/S2H2Z2 - 7. This was identical
to the second regimen in all other respects.
The dosages in the daily phase were: streptomycin, 0.75 g; isoniazid, 400 mg; rifampicin,
10 mg/kg body-weight and pyrazinamide, 40 mg/kg. In the twice-weekly phase the dosages were
streptomycin, 0.75 g; isoniazid, 15 mg/kg and pyrazinamide, 70 mg/kg. Pyridoxine, 6 mg, was ad-
ministered with each dose of isoniazid in both the daily and intermittent phases.
In the past, steroids have been used by several workers in standard chemotherapy with equivocal
results. They have not been so far used in short-course chemotherapy. It was thought that the im-
munosuppressive effect of steroids on the host might lead to multiplication of dormant bacilli, thus
rendering them susceptible to the bactericidal effect of the antituberculosis drugs.
In order to investigate this possibility, half the patients in each regimen, selected at random
were prescribed a steroid - prednisolone - as adjuvant during the initial phase. The dosage of
prednisolone was 20 mg, three times a day, in the first week and was tapered off gradually.
In all, there were 558 eligible patients with pretreatment drug-sensitive cultures in the study. Of
these, 4 patients died within the first week. Four others died of non-tuberculous causes, having ne-
gative sputum cultures at the time or death. Chemotherapy was changed on account of drug toxicity
in 4 cases, and 16 patients were grossly irregular.
The main comparisons of therapeutic efficacy are based on the remaining 530 patients, namely
129 SHRZ/S2H2Z2 - 5,132 SHRZ/S2H2Z
2 - 7 and 269 SHZ/S2H2Z2 - 7 patients.
The degree of regularity was high in all three series. Thus in each series, more than 90% of the pa-
tients had received more than 80% of their scheduled chemotherapy.
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The proportion of patients with all cultures negative at each month of treatment was higher with
the rifampicin regimens combined than with the non-rifampicin regimen during the first 2 months
(at 1 month, 50% compared with 31%; at 2 months 92% and 74%). The differences at both these
months namely 1% in the first and 18% in the second, are statistically significant. There was no
difference in the subsequent months. It is also worthy of note that at the end of therifampicin
phase (i.e. 2 months), 92% of the patients had all cultures negative.
The proportion of patients with favourable response at the end of treatment was 100% with each
of the regimens.
There did not appear to be any difference between the steroid and non-steroid groups treated with
the rifampicin regimens. In the non-rifampicin regimen, however, there was a suggestion that the
proportion culture-negative was higher in the steroid group during the first month. The difference,
however, is not significant.
The patients who completed their chemotherapy are all being followed up to a period of 60 months.
Results of follow-up for 18 months are now available.
Five per cent (5%) of 129 patients on regimen SHRZ/S2H2Z2 - 5 had a bacteriological relapse.
Sane of 104 patients on regimen SHRZ/S2H2Z2 - 7 had a relapse within this period. This regimen
would therefore appear to be a sterilizing one. Among patients on regimen SHZ/S2H2Z2 - 7, 4%
had a bacteriological relapse. None of the relapse rates are high and the results of the non-rifampicin
regimen may be considered as particularly encouraging.
We are reasonably confident, based on experience with shortcourse regimens elsewhere, that
these relapse rates are unlikely to increase during the latter period of follow-up. All patients who
had a relapse did so with cultures sensitive to streptomycin and isoniazid and could therefore be
retreated with standard drugs.
There were, in all, 115 patients who had drug-resistant cultures at the time they were admitted to
the study.
Considering the non-rifampicin regimen, all the 12 patients with streptomycin resistance had a
favourable response, compared with 12 to 18 with resistance to isoniazid alone and 4 of 25 with
resistance to both streptomycin and isoniazid. Thus, resistance to streptomycin alone was of no
consequence but resistance to isoniazid either alone or with resistance to streptomycin was asso-
ciated with an unfavourable prognosis. Correspondingly, in patients treated with the rifampicin
regimens, 17 of 19 patients with resistance to isoniazid alone and 18 of 26 patients with resistance
to both drugs had a favourable response. Thus, the fourth drug, rifampicin, has been largely success-
ful in compensating for streptomycin and isoniazid. In all, 78 patients had a favourable response
at the end of chemotherapy and relapse occurred in 3 of them, i.e., 4%. Thus, the relapse rates were
no higher than in patients who had drug-sensitive cultures initially.
In the present study, it had been planned to admit patients with a history of previous chemothe-
rapy up to 3 months. The 530 patients with drug-sensitive cultures reported so far had no chemo-
therapy or had at best received chemotherapy up to 2 weeks. There were, in addition, 22 patients
with pretreatment drug-sensitive cultures who had had up to 3 months of specific chemotherapy.
Thus, there were 667 patients in all. Of these, 115 (17%) had resistance to at least one drug. Despite
the high level of drug resistance, the two rifampicin regimens were highly effective - 96%-98% -
and the efficacy of the non-rifampicin regimen was only slightly lower, namely, 92%.
Considering adverse reactions to drugs, jaundice occurred in 15 (3%) of 530 patients; the inci-
dence was similar in the rifampicin and the non-rifamicin regimen, either with or without predniso-
lone, and could not be attributed to any drug. Fourteen per cent (14%) of patients in the rifampicin
series complained of arthralgia. Correspondingly, 34% in the non-rifampicin series had similar com-
plaints. This difference is highly significant, suggesting that the concurrent administration of rifam-
picin may have had an ameliorating effect on arthralgia due to pyrazinamide.
Prednisolone did not appear to have influenced the incidence of arthralgia.
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In total, serious toxicity requiring either reduction in dosage or termination occurred in 29 (6%     
patients, including 23 (5%) due to streptomycin, 3 due to isoniazid and 3 due to pyrazinamide.
In summary:
1. The three regimens investigated were all 100% effective at the end of chemotherapy and were 
associated with low relapse rates, namely 0-5%, in about a year of follow-up.
2. The SHRZ/S2H2Z2 - 7 was the most effective regimen with no relapses so far. Reducing the 
duration of chemotherapy with the rifampicin regimen or dropping off rifampicin carried only
small penalty of up to 5% relapses.
3. The non-rifampicin regimen has the vital advantage of a lower cost and is therefore particularly
suitable for application in developing countries.
4. The administration of prednisolone for2 months did not effect the speed of sputum conversion
in any regimen.
The present study has shown that a 5-month regimen containing rifampicin and a 7-month reg-
men without rifampicin are both highly effective. We are. however, greatly encouraged by the find-
ings and are planning to undertake studies to shorten the duration further.
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